Chief Legal Officer and Corporate Secretary · Cerevel Therapeutics Holdings, Inc. (CERE)

Scott Akamine

FY2021 is the first fiscal year CompBrief holds for Scott Akamine as a named executive officer of Cerevel Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$3,194,740

Salary $260,536Stock awards $0Bonus $50,000

5th of 7 named executive officers at Cerevel Therapeutics by FY2021 total.

7 named officers on file for Cerevel Therapeutics, FY2021

Scott Akamine’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • CERE’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cerevel Therapeutics’s whole pay program stands against its peers

  • Cerevel Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CERE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-20.

Free

Get Scott Akamine’s full pay file as a PDF — free

More than this page: up to 10 years of Scott’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Scott Akamine compensation by year

Cerevel Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Cerevel Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$260,536
Bonus$50,000
Stock awards$0
Option awards$2,749,997
Non-equity incentive$118,907
Pension and deferred compensation$0
All other$15,300
Total$3,194,740

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cerevel Therapeutics Holdings, Inc. DEF 14A filed April 28, 2022, accession 0001193125-22-127554, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Cerevel Therapeutics Holdings, Inc. filed document, accession 0001193125-22-127554. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option281,762—$13.17

Per the Outstanding Equity Awards at Fiscal Year-End table in Cerevel Therapeutics Holdings, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

15 Form 4 lines since the FY2021 proxy (filed April 28, 2022)
current to 2026-11-20 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-08-01Disposition to the issuer derivative—59,171$0.000
2024-08-01Disposition to the issuer—7,527—0
2024-08-01Disposition to the issuer derivative—367,126—0
2024-01-19Grant or award derivative—59,171$0.0059,171
2023-12-20Sale—7,072$41.427,237
2023-12-19Exercise or conversion—13,796—14,309
2023-12-19Exercise or conversion derivative—13,796$0.000
2023-12-07Exercise or conversion derivative10b5-110,000$0.00254,262

The 8 most recent of 15 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Cerevel Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
N. Anthony ColesChairperson and Chief Executive Officer (1)$8,108,335
Abraham CeesayPresident$5,276,631
Kathy YiFormer Chief Financial Officer$3,501,169
Raymond SanchezChief Medical Officer$3,416,287
Scott Akamine · this pageChief Legal Officer and Corporate Secretary$3,194,740
John RengerChief Scientific Officer$3,093,750
Mark BodenraderInterim Chief Financial Officer, Vice President, Finance and Chief Accounting Officer$1,312,994

The full Cerevel Therapeutics compensation record

free company brief

This page is one person within Cerevel Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Cerevel Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cerevel Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Scott Akamine's compensation dossier · One-time report. No refunds.